Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

DBD vs NCNO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NCNO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

NCNO Overall Winner 6-Pillar Tally: DBD 2 – 4 NCNO Matrix Metrics: DBD 4 – 6 NCNO

As of Nov 17, 2026, nCino, Inc. (NCNO) is the stronger overall head-to-head candidate over Diebold Nixdorf, Incorporated (DBD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). DBD carries a Unified Composite Score of 41.7/100 (SELL) at $52.62 (8.6x Forward P/E, 9.0% operating margin), whereas NCNO carries 54.6/100 (HOLD) at $22.27 (22.2x Forward P/E, 8.2% operating margin).

  • Technical & Structure Timing Caution: DBD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.1); meanwhile NCNO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DBD vs NCNO
DBD NYSE
Diebold Nixdorf, Incorporated
Calculating & Accounting Machines (No Electronic Computers)
$52.62
-0.46% 1D
Market Cap $1.8B
TTM Revenue $3.92B
Forward P/E 8.6x
Beta / 30D Vol 1.02β · 59% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 33.0 Fund 48.0 Flow 58.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 30
RSI-14: 30.1 · SMA20: $59.52 · SMA50: $62.36
NCNO NASDAQ Head-to-Head Winner
nCino, Inc. Common Stock
Services-Prepackaged Software
$22.27
-2.24% 1D
Market Cap $2.4B
TTM Revenue $622M
Forward P/E 22.2x
Beta / 30D Vol 0.40β · 38% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 38.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 53
RSI-14: 53.1 · SMA20: $22.79 · SMA50: $21.19

6-Pillar Scorecard Institutional Category Breakdown (DBD 2 – 4 NCNO)

Columns: Metric · DBD · NCNO
1. Valuation Multiples DBD
Forward P/E 8.6x 22.2x
Trailing P/E 26.1x 71.1x
PEG Ratio N/M N/M
EV / Revenue 0.7x 4.3x
2. Growth & Scale NCNO
Revenue Growth (YoY) +5.2% +8.2%
Earnings Growth (YoY) -82.9% +147.6%
TTM Revenue (USD) $3.92B $622M
Market Cap $1.8B $2.4B
3. Profitability & Quality DBD
Gross Margin 26.0% 62.2%
Operating Margin 9.0% 8.2%
Net Profit Margin 2.0% 5.4%
Return on Equity (ROE) 7.7% 3.9%
4. Balance Sheet & Cash Flow NCNO
Cash Generation (TTM) $127M $132M
Cash Flow Margin 3.2% 21.2%
Net Cash / Leverage $764M Net Debt (1.01x D/E) $255M Net Debt (0.36x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NCNO
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 45.7% (10th %ile) 55.7% (20th %ile)
Put/Call OI Skew 1.08x (Balanced) 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat NCNO
OpEx & R&D Intensity 17.0% of Rev ($667M) 54.0% of Rev ($336M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Software - Application Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DBD (4) vs NCNO (6)
Institutional Metric DBD NCNO Criterion Row Edge
Market Capitalization
Scale
$1.8B $2.4B Larger Scale NCNO
Trailing P/E Ratio
Valuation
26.1x 71.1x Lower Multiple DBD
Forward P/E Ratio
Valuation
8.6x 22.2x Lower Multiple DBD
Revenue Growth (YoY)
Growth
+5.2% +8.2% Higher Growth NCNO
Operating Margin (TTM)
Profitability
9.0% 8.2% Higher Margin DBD
Net Profit Margin
Profitability
2.0% 5.4% Higher Margin NCNO
Return on Equity (ROE)
Capital Efficiency
7.7% 3.9% Higher ROE DBD
52-Week Range Position
Momentum
2% ($52–$92) 62% ($14–$28) Stronger Trend NCNO
Beta / 30D Volatility
Risk Regime
1.02β · 59% Vol 0.40β · 38% Vol Lower Realized Risk NCNO
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 54.6 / 100 (HOLD) Higher Composite NCNO
Trailing 12M Revenue (USD)
Operating Scale
$3.92B $622M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
26.0% 62.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · 4.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$127M ($764M Net Debt (1.01x D/E)) $132M ($255M Net Debt (0.36x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NCNO +31.55 pp
DBD: -22.12% · NCNO: +9.43%
3M Horizon NCNO +29.58 pp
DBD: -21.94% · NCNO: +7.64%
6M Horizon NCNO +71.45 pp
DBD: -23.48% · NCNO: +47.97%
1Y Horizon NCNO +6.41 pp
DBD: -19.15% · NCNO: -12.74%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DBD Revenue NCNO Revenue DBD Op. Margin NCNO Op. Margin Margin Leader
FY2019 $4.41B N/A -0.6% N/A DBD
FY2020 $3.90B $140M 0.6% -20.4% DBD
FY2021 $3.91B $200M 3.5% -20.9% DBD
FY2022 $3.46B $270M -6.1% -26.1% DBD
FY2023 N/A $410M N/A -23.0% NCNO
FY2024 $3.75B $480M 4.9% -8.3% DBD
FY2025 $3.81B $540M 6.4% -3.4% DBD
FY2026 N/A $590M N/A 0.6% NCNO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DBD BREAKDOWN
79d in phase · OBV NEUTRAL
Current IV 45.7%
IV Percentile 10th %ile
Put/Call OI Skew 1.08x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DBD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NCNO CONSOLIDATION
52d in phase · OBV DISTRIBUTION
Current IV 55.7%
IV Percentile 20th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NCNO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DBD Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $1.8B market capitalization and 9.0% operating margin.
OpEx & R&D Reinvestment 17.0% of Rev ($667M)
90D Engineering Disclosures 0 Published
NCNO Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $2.4B market capitalization and 8.2% operating margin.
OpEx & R&D Reinvestment 54.0% of Rev ($336M)
90D Engineering Disclosures 0 Published

Investor FAQ DBD vs NCNO Key Questions & Quantitative Answers

As of Nov 17, 2026, nCino, Inc. (NCNO) is the stronger overall head-to-head candidate over Diebold Nixdorf, Incorporated (DBD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). DBD carries a Unified Composite Score of 41.7/100 (SELL) at $52.62 (8.6x Forward P/E, 9.0% operating margin), whereas NCNO carries 54.6/100 (HOLD) at $22.27 (22.2x Forward P/E, 8.2% operating margin). Technical & Structure Timing Caution: DBD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.1); meanwhile NCNO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NCNO leads the Growth & Scale pillar: DBD posts +5.2% YoY revenue growth and -82.9% YoY earnings growth on $3.92B TTM revenue (26.0% gross margin, 9.0% operating margin), compared with NCNO at +8.2% YoY revenue growth and +147.6% YoY earnings growth on $622M TTM revenue (62.2% gross margin, 8.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), DBD cumulative revenue shifted -13.6% while NCNO shifted +321.4%. In operating R&D and SG&A reinvestment, DBD deploys 17.0% of Rev ($667M) (0 90-day corporate R&D disclosures) versus 54.0% of Rev ($336M) (0 disclosures) for NCNO.

DBD screens cheaper on headline valuation multiples. DBD trades at 8.6x Forward P/E, 26.1x Trailing P/E, N/M PEG, and 0.7x EV/Revenue (3.2% FCF margin), whereas NCNO trades at 22.2x Forward P/E, 71.1x Trailing P/E, N/M PEG, and 4.3x EV/Revenue (21.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DBD (7.7% ROE) versus NCNO (3.9% ROE) capital efficiency.

In options market volatility and institutional positioning, DBD carries 45.7% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.08x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.02β · 59% Vol realized risk). By comparison, NCNO carries 55.7% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.40β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.